Exposure−response modelling for empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in patients with type 2 diabetes

AIMS: To provide model-based clinical development decision support including dose selection guidance for empagliflozin, an orally administered sodium glucose cotransporter 2 inhibitor, through developed exposure−response (E−R) models for efficacy and tolerability in patients with type 2 diabetes mel...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Br J Clin Pharmacol
Prif Awduron: Riggs, Matthew M, Seman, Leo J, Staab, Alexander, MacGregor, Thomas R, Gillespie, William, Gastonguay, Marc R, Woerle, Hans J, Macha, Sreeraj
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: BlackWell Publishing Ltd 2014
Pynciau:
Pharmacokinetic Dynamic Relationships
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC4256629/
https://ncbi.nlm.nih.gov/pubmed/24964723
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.12453
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg